Company intelligence / Profile preview

Anaconda Group

Barcelona, Catalonia, Spainanacondastores.com ↗

Ownership: Private
Development stage: Commercial

Overview

Anaconda Biomed has developed the ANA Funnel Catheter, a next-generation mechanical thrombectomy device for treating acute ischemic stroke. The device has demonstrated safety and efficacy in preclinical and initial clinical studies. It received CE Mark approval in June 2025, enabling commercialization across Europe. The company is conducting the ATHENA clinical trial to support FDA approval in the United States.

Therapeutic areas: Neurology
Modalities: Device (specifically, mechanical thrombectomy system/catheter)
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Anaconda Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anaconda Group.

Explore the full profile